Release date: 2024-08-14 17:18:01 Article From: Lucius Laos Recommended: 146
Venetoclax restores normal apoptosis of cancer cells by blocking the anti-apoptotic function of the BCL-2 protein. Indications include chronic lymphocytic leukemia, acute myeloid leukemia, etc.
The precautions that patients should know before using the medication as prescribed are as follows:
In one study, venetoclax was found to be used in combination with bortezomib and dexamethasone to increase mortality in patients with multiple myeloma. Therefore, the combination of venetoclax with bortezomib and dexamethasone is not recommended for the treatment of multiple myeloma, except in controlled clinical trials.
During the treatment of chronic lymphocytic leukemia (CLL) with venetoclax, 63% to 64% of patients have been observed to develop more severe neutropenia with severity of grade 3 or 4, especially in 31% to 33% of patients who experience more severe grade 4 neutropenia. Another 4% to 6% of patients may have febrile neutropenia.
This significant decrease in neutrophil levels significantly increases the risk of infection in patients, and careful infection prevention and monitoring in these patients is particularly important.
In addition to the precautions for the use of the drug, it is equally important to understand the indications for venetoclax.
Venetoclax is suitable for adult patients and is primarily used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine is indicated for adults with newly diagnosed acute myeloid leukemia (AML), particularly those over 75 years of age or who are unable to receive intensive induction chemotherapy for health reasons.
Venetoclax has shown remarkable efficacy in the treatment of related diseases, but some adverse effects are inevitable during medication:
The number of red blood cells is reduced or malfunctioning, which may make the person feel tired, weak, or dizzy. Treatment may require iron supplementation, erythropoietin, or blood transfusions.
Such as colds, sore throats or sinusitis may occur more often when the immune system is suppressed. Treatment with antibiotics or antiviral drugs is usually required.
[Warm tips] The treatment of the disease is a long-term process, and patients should maintain a positive and optimistic attitude during the treatment process, communicate with the doctor in time if there are any questions or discomforts, and obtain professional medical advice.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: